Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn's disease.
OBJECTIVE
To study the influence of food on the systemic availability of budesonide in patients with active Crohn's disease.


METHODS
Eight patients with an established diagnosis of Crohn's disease each received 9 mg budesonide controlled ileal release (CIR) capsules (Entocort capsules) orally on two separate occasions: once in a fasting state and once after a heavy breakfast. For reference, deuterium-labelled ((2)H(8)) budesonide, 0.5 mg, was given intravenously. Plasma concentrations of budesonide and (2)H(8)-budesonide were determined for 12 h, and their pharmacokinetic parameters were calculated.


RESULTS
Average systemic availability of budesonide during fasting conditions was 10.7%, area under the curve was 27.5 nmol/L x h and peak plasma concentration was 4.1 nmol/L. Corresponding postprandial values were 13.2%, 27.0 nmol/L x h and 3. 8 nmol/L. Food increased the mean absorption time from 4.5 to 6.8 h (P=0.0012). Body clearance of budesonide was about 25% higher after eating (P=0.0015).


CONCLUSIONS
Food had little influence on systemic availability and peak plasma concentrations of budesonide administered in CIR capsules. Absorption was retarded postprandially, likely due to delayed gastric emptying. Budesonide in CIR capsules can be administered at the same dose regardless of prandial status in patients with Crohn's disease.
Lundin
P
P
AstraZeneca R & D Lund, Lund, Sweden. Pal.Lundin@astrazeneca.com
Naber
T
T
Nilsson
M
M
Edsbäcker
S
S
D000284:Administration, Oral; D000328:Adult; D019819:Budesonide / Q000008:administration & dosage / Q000493:pharmacokinetics*; D002214:Capsules; D003424:Crohn Disease / Q000188:drug therapy*; D018592:Cross-Over Studies; D005260:Female; D005502:Food; D006801:Humans; D007082:Ileum / Q000378:metabolism; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged
D002214:Capsules; D019819:Budesonide